yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q36989067-4C31D18A-F567-40F2-A17B-E0EBB2C5FC88
Q36989067-4C31D18A-F567-40F2-A17B-E0EBB2C5FC88
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36989067-4C31D18A-F567-40F2-A17B-E0EBB2C5FC88
Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.
P2860
Q36989067-4C31D18A-F567-40F2-A17B-E0EBB2C5FC88
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36989067-4C31D18A-F567-40F2-A17B-E0EBB2C5FC88
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d2d08c24e356bef03bc38043703b0e30ac6d2617
P2860
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.